NCT05360680 - A Phase 1 in Patients With HLA-A*0201+ and WT1+ Recurrent/Metastatic Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2022

Primary Completion Date

March 12, 2025

Study Completion Date

March 12, 2025

Conditions

Colorectal CancerGastric CancerPancreatic CancerOvarian Cancer

Interventions

DRUG

CUE-102

CUE-102 is a novel fusion protein developed for the treatment of patients with WT1-positive malignancies.

Trial Locations (15)

Montefiore Medical Center, The Bronx

Johns Hopkins University, Baltimore

Carolina BioOncology Institute, Huntersville

Winship Cancer Institute, Atlanta

Moffitt Cancer Center, Tampa

Cleveland Medical Center (University Hospitals), Cleveland

Gabrail Cancer Center, Canton

Carbone Cancer Center, Madison

Mayo Clinic - Rochester, Rochester

MD Anderson Cancer Center, Houston

Mayo Clinic, Phoenix

Cedars-Sinai Medical Center, Los Angeles

Stanford Advanced Medicine Cancer Center, Palo Alto

Northwest Medical Specialties, PLLC, Tacoma

Carol G. Simon Cancer Center - Morristown Medical Center, Morristown